Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...

March 11 (Reuters) - Pfizer (PFE.N), opens new tab and Arvinas' (ARVN.O), opens new tab experimental treatment failed to delay progression of breast cancer in patients with most common type of the ...

Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in ...